Health Care [ 4/12 ] | Biotechnology [ 18/72 ]
NASDAQ | Common Stock
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for endocrine diseases and endocrine-related tumors.
The company's lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs).
It is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases.
The company was incorporated in 2008 and is headquartered in San Diego, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 9, 24 | -0.93 Decreased by -9.41% | -0.81 Decreased by -14.81% |
| Mar 12, 24 | -0.90 Decreased by -7.14% | -0.86 Decreased by -4.65% |
| Nov 7, 23 | -1.01 Decreased by -29.49% | -0.86 Decreased by -17.44% |
| Aug 8, 23 | -0.94 Decreased by -16.05% | -0.86 Decreased by -9.30% |
| May 4, 23 | -0.85 Decreased by -19.72% | -0.81 Decreased by -4.94% |
| Feb 28, 23 | -0.84 Decreased by -23.53% | -0.82 Decreased by -2.44% |
| Nov 14, 22 | -0.78 Decreased by -6.85% | -0.83 Increased by +6.02% |
| Aug 12, 22 | -0.81 Decreased by -15.71% | -0.67 Decreased by -20.90% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 346.00 K Decreased by -24.45% | -57.46 M Decreased by -42.24% | Decreased by -16.61 K% Decreased by -88.28% |
| Jun 30, 23 | 988.00 K Increased by +125.06% | -50.98 M Decreased by -22.24% | Decreased by -5.16 K% Increased by +45.69% |
| Mar 31, 23 | 2.68 M Decreased by -14.44% | -44.01 M Decreased by -24.23% | Decreased by -1.64 K% Decreased by -45.19% |
| Dec 31, 22 | 709.00 K Decreased by -34.23% | -42.43 M Decreased by -37.77% | Decreased by -5.98 K% Decreased by -109.48% |
| Sep 30, 22 | 458.00 K Increased by +7.26 K% | -40.40 M Decreased by -45.04% | Decreased by -8.82 K% Increased by +98.03% |
| Jun 30, 22 | 439.00 K Increased by +7.74 K% | -41.70 M Decreased by -59.82% | Decreased by -9.50 K% Increased by +97.96% |
| Mar 31, 22 | 3.13 M Increased by +N/A% | -35.43 M Decreased by -54.70% | Decreased by -1.13 K% Decreased by N/A% |
| Dec 31, 21 | 1.08 M Increased by +N/A% | -30.79 M Decreased by -42.29% | Decreased by -2.86 K% Decreased by N/A% |